牛牛AI助理已提取核心訊息
Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business...Show More
Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business time to the role. The press release emphasizes Goodman's extensive experience and successful track record, particularly in the addiction space, as Adial advances the AD04 clinical program and prepares for potential commercialization. Goodman's previous roles include leadership positions at Indivior PLC and Reckitt Benckiser Pharmaceuticals, where he contributed to significant revenue growth in the addiction market.
阿迪爾製藥公司於2024年1月18日宣佈任命託尼·古德曼爲公司首席運營官（COO）。古德曼是一位經驗豐富的製藥行業高管，自2017年起擔任Adial董事會成員，他將負責監督戰略增長計劃，包括Adial的主要酒精使用障礙（AUD）研究藥物AD04的臨床開發和商業規劃。他還將重點關注旨在爲戒毒治療提供合作機會的業務發展計劃。古德曼的任命是在他與他創立的凱西克集團有限責任公司簽訂的《主服務協議》的《工作聲明》#2 中同意擔任首席運營官之後作出的。他將獲得每月25,000美元的薪酬，並將至少75％的工作時間用於該職位。新聞稿強調了隨着Adial推進AD04臨床項目併爲潛在的商業化做準備，古德曼的豐富經驗和成功記錄，尤其是在成癮領域。古德曼之前的職位包括在Indivior PLC和Reckitt Benckiser Pharmicals擔任領導職務，他在那裏爲成癮市場的顯著收入增長做出了貢獻。
阿迪爾製藥公司於2024年1月18日宣佈任命託尼·古德曼爲公司首席運營官（COO）。古德曼是一位經驗豐富的製藥行業高管，自2017年起擔任Adial董事會成員，他將負責監督戰略增長計劃，包括Adial的主要酒精使用障礙（AUD）研究藥物AD04的臨床開發和商業規劃。他還將重點關注旨在爲戒毒治療提供合作機會的業務發展計劃。古德曼的任命是在他與他創立的凱西克集團有限責任公司簽訂的《主服務協議》的《工作聲明》#2 中同意擔任首席運營官之後作出的。他將獲得每月25,000美元的薪酬，並將至少75％的工作時間用於該職位。新聞稿強調了隨着Adial推進AD04臨床項目併爲潛在的商業化做準備，古德曼的豐富經驗和成功記錄，尤其是在成癮領域。古德曼之前的職位包括在Indivior PLC和Reckitt Benckiser Pharmicals擔任領導職務，他在那裏爲成癮市場的顯著收入增長做出了貢獻。
有用
沒用